

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

| | |
|-----------------------|----------------|
| SUBMISSION TYPE: | NEW ASSIGNMENT |
| NATURE OF CONVEYANCE: | MERGER |
| EFFECTIVE DATE: | 10/01/2006 |

CONVEYING PARTY DATA

| Name | Execution Date |
|------------------------------------|----------------|
| The Institute for Genomic Research | 10/02/2007 |

RECEIVING PARTY DATA

| | |
|-----------------|---------------------------------|
| Name: | J. Craig Venter Institute, Inc. |
| Street Address: | 9704 Medical Center Drive |
| City: | Rockville |
| State/Country: | MARYLAND |
| Postal Code: | 20850 |

PROPERTY NUMBERS Total: 7

| Property Type | Number |
|----------------|---------|
| Patent Number: | 5650295 |
| Patent Number: | 6294328 |
| Patent Number: | 6462188 |
| Patent Number: | 6503729 |
| Patent Number: | 6537773 |
| Patent Number: | 7138569 |
| Patent Number: | 6797466 |

CORRESPONDENCE DATA

Fax Number: (240)268-4002
Correspondence will be sent via US Mail when the fax attempt is unsuccessful.
 Phone: 301-795-7543
 Email: chaywood@jcvl.org
 Correspondent Name: Claudia Haywood
 Address Line 1: 9704 Medical Center Drive
 Address Line 2: Legal Dept.

CH \$280.00 5650295

Address Line 4: Rockville, MARYLAND 20850

NAME OF SUBMITTER:

Claudia Haywood

Total Attachments: 7

source=assignment328#page1.tif

source=assignment 188#page1.tif

source=assignment 295#page1.tif

source=assignment 466#page1.tif

source=assignment 569#page1.tif

source=assignment 729#page1.tif

source=assignment 773#page1.tif

ASSIGNMENT

WHEREAS, the undersigned, The Institute for Genomic Research (TIGR) (hereinafter "ASSIGNOR"), is the lawful owner of the patent entitled: DNA SEQUENCES FOR STRAIN ANALYSIS IN MYCOBACTERIUM TUBERCULOSIS issued on September 25, 2001 in the United States Patent and Trademark Office having Patent No. 6,294,328; and

WHEREAS, the J. Craig Venter Institute (hereinafter "ASSIGNEE"), a corporation duly organized and existing under the laws of Maryland and having its principal office and place of business at 9704 Medical Center Drive, Rockville, Maryland 20850 has merged with TIGR effective October 1, 2006 and is the successor-in-interest organization and has acquired the entire right, title and interest to all TIGR assets including the above referenced patent; and

NOW, THEREFORE, in consideration of One Dollar (\$1.00) and other good and valuable consideration, the receipt of which is hereby acknowledged, said ASSIGNOR does hereby sell, assign, and transfer, and hereby set over unto ASSIGNEE, its successors, assigns and legal representatives, the full and exclusive right, title and interest to said invention in the United States of America and all foreign countries, including, without limitation, said invention as described in the aforesaid application, to be held and enjoyed by said ASSIGNEE, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by said ASSIGNOR had this assignment and sale not been made, including, without limitation, all rights to the aforesaid application and to any United States Letters Patent therefore, when issued together with all improvements thereon and betterments thereof, all related applications including, but not limited to, divisions, continuations, continuations-in-part, reissue and reexaminations thereof and substitutions of or for said application, and all foreign rights including the right to make application for Letters Patent for said inventions in any and all foreign countries and the right to claim priority as to the filing date under the International Convention on the basis for the aforesaid application for United State Letters Patent; and ASSIGNOR hereby authorizes and requests the Commissioner of Patents to record in its record the assignment of all Letters Patent to ASSIGNEE for its interest as ASSIGNEE, its successors, assigns and legal representatives.

ASSIGNOR hereby agrees to execute any papers, provide any information and testify in any interference or litigation at the request of ASSIGNEE, its successors, assigns and legal representatives, when deemed essential to ASSIGNEE, its successors, assigns and legal representatives, when deemed essential to ASSIGNEE, its successors', assigns' and legal representatives' full enjoyment, protection, enforcement and title in and to such invention and rights hereby transferred.

ASSIGNOR furthermore agrees upon request of said ASSIGNEE, its successors, assigns and legal representatives, and without further remuneration, to execute any and all papers desired by said ASSIGNEE, its successors, assigns and legal representatives, for the filing and granting of foreign applications and the perfecting of title thereto in said ASSIGNEE, its successors, assigns and legal representatives.

THE INSTITUTE FOR GENOMIC RESEARCH

By:  _____

Date Signed: 10/2/07

Aimee Turner

Chief Financial Officer, TIGR

ASSIGNMENT

WHEREAS, the undersigned, The Institute for Genomic Research (TIGR) (hereinafter "ASSIGNOR"), is the lawful owner of the patent entitled: HUMAN 5-HT3 RECEPTOR issued on October 8, 2002 in the United States Patent and Trademark Office having Patent No. 6,462,188; and


WHEREAS, the J. Craig Venter Institute (hereinafter "ASSIGNEE"), a corporation duly organized and existing under the laws of Maryland and having its principal office and place of business at 9704 Medical Center Drive, Rockville, Maryland 20850 has merged with TIGR effective October 1, 2006 and is the successor-in-interest organization and has acquired the entire right, title and interest to all TIGR assets including the above referenced patent; and

NOW, THEREFORE, in consideration of One Dollar (\$1.00) and other good and valuable consideration, the receipt of which is hereby acknowledged, said ASSIGNOR does hereby sell, assign, and transfer, and hereby set over unto ASSIGNEE, its successors, assigns and legal representatives, the full and exclusive right, title and interest to said invention in the United States of America and all foreign countries, including, without limitation, said invention as described in the aforesaid application, to be held and enjoyed by said ASSIGNEE, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by said ASSIGNOR had this assignment and sale not been made, including, without limitation, all rights to the aforesaid application and to any United States Letters Patent therefore, when issued together with all improvements thereon and betterments thereof, all related applications including, but not limited to, divisions, continuations, continuations-in-part, reissue and reexaminations thereof and substitutions of or for said application, and all foreign rights including the right to make application for Letters Patent for said inventions in any and all foreign countries and the right to claim priority as to the filing date under the International Convention on the basis for the aforesaid application for United State Letters Patent; and ASSIGNOR hereby authorizes and requests the Commissioner of Patents to record in its record the assignment of all Letters Patent to ASSIGNEE for its interest as ASSIGNEE, its successors, assigns and legal representatives.

ASSIGNOR hereby agrees to execute any papers, provide any information and testify in any interference or litigation at the request of ASSIGNEE, its successors, assigns and legal representatives, when deemed essential to ASSIGNEE, its successors, assigns and legal representatives, when deemed essential to ASSIGNEE, its successors', assigns' and legal representatives' full enjoyment, protection, enforcement and title in and to such invention and rights hereby transferred.

ASSIGNOR furthermore agrees upon request of said ASSIGNEE, its successors, assigns and legal representatives, and without further remuneration, to execute any and all papers desired by said ASSIGNEE, its successors, assigns and legal representatives, for the filing and granting of foreign applications and the perfecting of title thereto in said ASSIGNEE, its successors, assigns and legal representatives.

THE INSTITUTE FOR GENOMIC RESEARCH

By:  _____

Date Signed: 10/2/07

Aimee Turner

Chief Financial Officer, TIGR

ASSIGNMENT

WHEREAS, the undersigned, The Institute for Genomic Research (TIGR) (hereinafter "ASSIGNOR"), is the lawful owner of the patent entitled: MACROPHAGE MIGRATION INHIBITORY FACTOR-3 issued on July 22, 1997 in the United States Patent and Trademark Office having Patent No. 5,650, 295; and


WHEREAS, the J. Craig Venter Institute (hereinafter "ASSIGNEE"), a corporation duly organized and existing under the laws of Maryland and having its principal office and place of business at 9704 Medical Center Drive, Rockville, Maryland 20850 has merged with TIGR effective October 1, 2006 and is the successor-in-interest organization and has acquired the entire right, title and interest to all TIGR assets including the above referenced patent; and

NOW, THEREFORE, in consideration of One Dollar (\$1.00) and other good and valuable consideration, the receipt of which is hereby acknowledged, said ASSIGNOR does hereby sell, assign, and transfer, and hereby set over unto ASSIGNEE, its successors, assigns and legal representatives, the full and exclusive right, title and interest to said invention in the United States of America and all foreign countries, including, without limitation, said invention as described in the aforesaid application, to be held and enjoyed by said ASSIGNEE, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by said ASSIGNOR had this assignment and sale not been made, including, without limitation, all rights to the aforesaid application and to any United States Letters Patent therefore, when issued together with all improvements thereon and betterments thereof, all related applications including, but not limited to, divisions, continuations, continuations-in-part, reissue and reexaminations thereof and substitutions of or for said application, and all foreign rights including the right to make application for Letters Patent for said inventions in any and all foreign countries and the right to claim priority as to the filing date under the International Convention on the basis for the aforesaid application for United State Letters Patent; and ASSIGNOR hereby authorizes and requests the Commissioner of Patents to record in its record the assignment of all Letters Patent to ASSIGNEE for its interest as ASSIGNEE, its successors, assigns and legal representatives.

ASSIGNOR hereby agrees to execute any papers, provide any information and testify in any interference or litigation at the request of ASSIGNEE, its successors, assigns and legal representatives, when deemed essential to ASSIGNEE, its successors, assigns and legal representatives, when deemed essential to ASSIGNEE, its successors', assigns' and legal representatives' full enjoyment, protection, enforcement and title in and to such invention and rights hereby transferred.

ASSIGNOR furthermore agrees upon request of said ASSIGNEE, its successors, assigns and legal representatives, and without further remuneration, to execute any and all papers desired by said ASSIGNEE, its successors, assigns and legal representatives, for the filing and granting of foreign applications and the perfecting of title thereto in said ASSIGNEE, its successors, assigns and legal representatives.

THE INSTITUTE FOR GENOMIC RESEARCH

By:  _____

Date Signed: 10/2/07

Aimee Turner

Chief Financial Officer, TIGR

ASSIGNMENT

WHEREAS, the undersigned, The Institute for Genomic Research (TIGR) (hereinafter "ASSIGNOR"), is the lawful owner of the patent entitled: COMPLETE GENOME SEQUENCE OF THE METHANOGENIC ARCHAEON, METHANOCOCCUS JANNASHII issued on September 28, 2004 in the United States Patent and Trademark Office having Patent No. 6,797,466; and

WHEREAS, the J. Craig Venter Institute (hereinafter "ASSIGNEE"), a corporation duly organized and existing under the laws of Maryland and having its principal office and place of business at 9704 Medical Center Drive, Rockville, Maryland 20850 has merged with TIGR effective October 1, 2006 and is the successor-in-interest organization and has acquired the entire right, title and interest to all TIGR assets including the above referenced patent; and

NOW, THEREFORE, in consideration of One Dollar (\$1.00) and other good and valuable consideration, the receipt of which is hereby acknowledged, said ASSIGNOR does hereby sell, assign, and transfer, and hereby set over unto ASSIGNEE, its successors, assigns and legal representatives, the full and exclusive right, title and interest to said invention in the United States of America and all foreign countries, including, without limitation, said invention as described in the aforesaid application, to be held and enjoyed by said ASSIGNEE, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by said ASSIGNOR had this assignment and sale not been made, including, without limitation, all rights to the aforesaid application and to any United States Letters Patent therefore, when issued together with all improvements thereon and betterments thereof, all related applications including, but not limited to, divisions, continuations, continuations-in-part, reissue and reexaminations thereof and substitutions of or for said application, and all foreign rights including the right to make application for Letters Patent for said inventions in any and all foreign countries and the right to claim priority as to the filing date under the International Convention on the basis for the aforesaid application for United State Letters Patent; and ASSIGNOR hereby authorizes and requests the Commissioner of Patents to record in its record the assignment of all Letters Patent to ASSIGNEE for its interest as ASSIGNEE, its successors, assigns and legal representatives.

ASSIGNOR hereby agrees to execute any papers, provide any information and testify in any interference or litigation at the request of ASSIGNEE, its successors, assigns and legal representatives, when deemed essential to ASSIGNEE, its successors, assigns and legal representatives, when deemed essential to ASSIGNEE, its successors', assigns' and legal representatives' full enjoyment, protection, enforcement and title in and to such invention and rights hereby transferred.

ASSIGNOR furthermore agrees upon request of said ASSIGNEE, its successors, assigns and legal representatives, and without further remuneration, to execute any and all papers desired by said ASSIGNEE, its successors, assigns and legal representatives, for the filing and granting of foreign applications and the perfecting of title thereto in said ASSIGNEE, its successors, assigns and legal representatives.

THE INSTITUTE FOR GENOMIC RESEARCH

By:  _____

Date Signed: 10/2/07

Aimee Turner

Chief Financial Officer, TIGR

ASSIGNMENT

WHEREAS, the undersigned, The Institute for Genomic Research (TIGR) (hereinafter "ASSIGNOR"), is the lawful owner of the patent entitled: NUCLEIC ACIDS ENCODING PSEUDOMONAS HOP PROTEINS AND USE THEREOF issued on November 21, 2006 in the United States Patent and Trademark Office having Patent No. 7,138,569; and


WHEREAS, the J. Craig Venter Institute (hereinafter "ASSIGNEE"), a corporation duly organized and existing under the laws of Maryland and having its principal office and place of business at 9704 Medical Center Drive, Rockville, Maryland 20850 has merged with TIGR effective October 1, 2006 and is the successor-in-interest organization and has acquired the entire right, title and interest to all TIGR assets including the above referenced patent; and

NOW, THEREFORE, in consideration of One Dollar (\$1.00) and other good and valuable consideration, the receipt of which is hereby acknowledged, said ASSIGNOR does hereby sell, assign, and transfer, and hereby set over unto ASSIGNEE, its successors, assigns and legal representatives, the full and exclusive right, title and interest to said invention in the United States of America and all foreign countries, including, without limitation, said invention as described in the aforesaid application, to be held and enjoyed by said ASSIGNEE, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by said ASSIGNOR had this assignment and sale not been made, including, without limitation, all rights to the aforesaid application and to any United States Letters Patent therefore, when issued together with all improvements thereon and betterments thereof, all related applications including, but not limited to, divisions, continuations, continuations-in-part, reissue and reexaminations thereof and substitutions of or for said application, and all foreign rights including the right to make application for Letters Patent for said inventions in any and all foreign countries and the right to claim priority as to the filing date under the International Convention on the basis for the aforesaid application for United State Letters Patent; and ASSIGNOR hereby authorizes and requests the Commissioner of Patents to record in its record the assignment of all Letters Patent to ASSIGNEE for its interest as ASSIGNEE, its successors, assigns and legal representatives.

ASSIGNOR hereby agrees to execute any papers, provide any information and testify in any interference or litigation at the request of ASSIGNEE, its successors, assigns and legal representatives, when deemed essential to ASSIGNEE, its successors, assigns and legal representatives, when deemed essential to ASSIGNEE, its successors', assigns' and legal representatives' full enjoyment, protection, enforcement and title in and to such invention and rights hereby transferred.

ASSIGNOR furthermore agrees upon request of said ASSIGNEE, its successors, assigns and legal representatives, and without further remuneration, to execute any and all papers desired by said ASSIGNEE, its successors, assigns and legal representatives, for the filing and granting of foreign applications and the perfecting of title thereto in said ASSIGNEE, its successors, assigns and legal representatives.

THE INSTITUTE FOR GENOMIC RESEARCH

By:  _____

Date Signed: 10/2/07

Aimee Turner
Chief Financial Officer, TIGR

ASSIGNMENT

WHEREAS, the undersigned, The Institute for Genomic Research (TIGR) (hereinafter "ASSIGNOR"), is the lawful owner of the patent entitled: SELECTED POLYNUCLEOTIDE AND POLYPEPTIDE SEQUENCES OF THE METHANOGENIC ARCHAEON, METHANOCOCCUS JANNASHII issued on January 7, 2003 in the United States Patent and Trademark Office having Patent No. 6,503,729; and

WHEREAS, the J. Craig Venter Institute (hereinafter "ASSIGNEE"), a corporation duly organized and existing under the laws of Maryland and having its principal office and place of business at 9704 Medical Center Drive, Rockville, Maryland 20850 has merged with TIGR effective October 1, 2006 and is the successor-in-interest organization and has acquired the entire right, title and interest to all TIGR assets including the above referenced patent; and

NOW, THEREFORE, in consideration of One Dollar (\$1.00) and other good and valuable consideration, the receipt of which is hereby acknowledged, said ASSIGNOR does hereby sell, assign, and transfer, and hereby set over unto ASSIGNEE, its successors, assigns and legal representatives, the full and exclusive right, title and interest to said invention in the United States of America and all foreign countries, including, without limitation, said invention as described in the aforesaid application, to be held and enjoyed by said ASSIGNEE, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by said ASSIGNOR had this assignment and sale not been made, including, without limitation, all rights to the aforesaid application and to any United States Letters Patent therefore, when issued together with all improvements thereon and betterments thereof, all related applications including, but not limited to, divisions, continuations, continuations-in-part, reissue and reexaminations thereof and substitutions of or for said application, and all foreign rights including the right to make application for Letters Patent for said inventions in any and all foreign countries and the right to claim priority as to the filing date under the International Convention on the basis for the aforesaid application for United State Letters Patent; and ASSIGNOR hereby authorizes and requests the Commissioner of Patents to record in its record the assignment of all Letters Patent to ASSIGNEE for its interest as ASSIGNEE, its successors, assigns and legal representatives.

ASSIGNOR hereby agrees to execute any papers, provide any information and testify in any interference or litigation at the request of ASSIGNEE, its successors, assigns and legal representatives, when deemed essential to ASSIGNEE, its successors, assigns and legal representatives, when deemed essential to ASSIGNEE, its successors', assigns' and legal representatives' full enjoyment, protection, enforcement and title in and to such invention and rights hereby transferred.


ASSIGNOR furthermore agrees upon request of said ASSIGNEE, its successors, assigns and legal representatives, and without further remuneration, to execute any and all papers desired by said ASSIGNEE, its successors, assigns and legal representatives, for the filing and granting of foreign applications and the perfecting of title thereto in said ASSIGNEE, its successors, assigns and legal representatives.

THE INSTITUTE FOR GENOMIC RESEARCH

By: 

Aimee Turner

Chief Financial Officer, TIGR

Date Signed: 

ASSIGNMENT

WHEREAS, the undersigned, The Institute for Genomic Research (TIGR) (hereinafter "ASSIGNOR"), is the lawful owner of the patent entitled: NUCLEOTIDE SEQUENCE OF THE MYCOPLASMA GENITALIUM GENOME, FRAGMENTS THEREOF, AND USES THEREOF issued on March 25, 2003 in the United States Patent and Trademark Office having Patent No. 6,537,773; and


WHEREAS, the J. Craig Venter Institute (hereinafter "ASSIGNEE"), a corporation duly organized and existing under the laws of Maryland and having its principal office and place of business at 9704 Medical Center Drive, Rockville, Maryland 20850 has merged with TIGR effective October 1, 2006 and is the successor-in-interest organization and has acquired the entire right, title and interest to all TIGR assets including the above referenced patent; and

NOW, THEREFORE, in consideration of One Dollar (\$1.00) and other good and valuable consideration, the receipt of which is hereby acknowledged, said ASSIGNOR does hereby sell, assign, and transfer, and hereby set over unto ASSIGNEE, its successors, assigns and legal representatives, the full and exclusive right, title and interest to said invention in the United States of America and all foreign countries, including, without limitation, said invention as described in the aforesaid application, to be held and enjoyed by said ASSIGNEE, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by said ASSIGNOR had this assignment and sale not been made, including, without limitation, all rights to the aforesaid application and to any United States Letters Patent therefore, when issued together with all improvements thereon and betterments thereof, all related applications including, but not limited to, divisions, continuations, continuations-in-part, reissue and reexaminations thereof and substitutions of or for said application, and all foreign rights including the right to make application for Letters Patent for said inventions in any and all foreign countries and the right to claim priority as to the filing date under the International Convention on the basis for the aforesaid application for United State Letters Patent; and ASSIGNOR hereby authorizes and requests the Commissioner of Patents to record in its record the assignment of all Letters Patent to ASSIGNEE for its interest as ASSIGNEE, its successors, assigns and legal representatives.

ASSIGNOR hereby agrees to execute any papers, provide any information and testify in any interference or litigation at the request of ASSIGNEE, its successors, assigns and legal representatives, when deemed essential to ASSIGNEE, its successors, assigns and legal representatives, when deemed essential to ASSIGNEE, its successors', assigns' and legal representatives' full enjoyment, protection, enforcement and title in and to such invention and rights hereby transferred.

ASSIGNOR furthermore agrees upon request of said ASSIGNEE, its successors, assigns and legal representatives, and without further remuneration, to execute any and all papers desired by said ASSIGNEE, its successors, assigns and legal representatives, for the filing and granting of foreign applications and the perfecting of title thereto in said ASSIGNEE, its successors, assigns and legal representatives.

THE INSTITUTE FOR GENOMIC RESEARCH

By: 

Aimee Turner

Chief Financial Officer, TIGR

Date Signed: 